Read this first
This is plain-language harm-reduction information, not medical advice. Peptides discussed here are research compounds; most are not approved for human use. People will use them either way — we would rather they have the facts.
On 23 and 24 July 2026 the FDA's Pharmacy Compounding Advisory Committee (PCAC) met to consider whether seven peptides should be added to the "503A bulks list", the list of ingredients that pharmacies may use when compounding for individual patients. According to the FDA's meeting page, the substances were BPC-157, KPV, TB-500 and MOTS-c on 23 July, and emideltide (DSIP), Semax and Epitalon on 24 July.
How the panel voted
AJMC reported narrow margins: 8 to 6 with one abstention for BPC-157, KPV and TB-500, and 7 to 5 with two abstentions for MOTS-c. It said Semax and Epitalon passed with similarly tight margins, while emideltide was rejected 7 to 6 with one abstention. The National Community Pharmacists Association likewise reported that the committee recommended six peptides: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax.
What the FDA's own scientists said
According to law firm Orrick, ahead of the meeting FDA career scientists recommended against inclusion for all seven, citing inadequate characterisation of the substances (including inconsistent naming and missing quality data) and insufficient or absent human clinical trial evidence. AJMC reported that the available research was described as short, small and insufficient to establish safety or effectiveness for the indications under review. STAT News noted that a majority of panelists who voted yes had ties to the peptide industry, and described the outcome as a victory for peptide advocates and Health Secretary Robert F. Kennedy Jr.
What this does not mean
- The votes are non-binding. The FDA is not obliged to follow them, though STAT noted it is unusual for the agency to go against its committees.
- Per AJMC, the FDA would still need notice-and-comment rulemaking (a proposed rule, comments and a final rule) before pharmacies could legally compound these substances. Orrick suggested that would typically take 12 to 24 months.
- No peptide is FDA-approved for these uses. A place on a compounding list is not an approval for safety or effectiveness.
Why it matters if you are considering these peptides
A favourable vote can be read as a green light. It is not one. Even in the best case, the outcome would be pharmacies making these peptides for individual patients under a prescription, rather than the vial-from-a-website route many people use today. The FDA's staff concern about quality and naming is relevant to anyone buying: if the regulator's own scientists cannot confirm what some of these substances are, an anonymous vendor's label certainly cannot.
This is a US process. It does not make these peptides approved medicines, and it is unrelated to anti-doping rules for athletes.
What is still unknown
Whether the FDA will accept the recommendations, how soon any rule might appear, and what conditions would apply. We also did not find a source for exact vote counts for Semax and Epitalon.
Our pages on BPC-157, TB-500, KPV, MOTS-c and Epitalon cover what the evidence does and does not show.
Common questions
Can US pharmacies now compound BPC-157?
Not yet, according to the sources. The committee vote is a non-binding recommendation, and rulemaking must be completed first.
Does the vote mean BPC-157 is proven safe?
No. FDA scientists said human evidence was insufficient, and the panel vote was close.
Sources
- FDA: July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee
- AJMC: FDA Panel Backs 6 Peptides for Compounding
- STAT News: FDA panel backs compounded BPC-157, KPV peptides in win for RFK Jr.
- Orrick: FDA Peptide Compounding Vote - What to Watch at the July PCAC Meeting
- NCPA: FDA advisory committee nominates six peptides for pharmacies to compound